Remove 2030 Remove Dosage Remove Pharmaceutical Companies
article thumbnail

OSD contract manufacturing market valued at $54.7 billion by 2030

European Pharmaceutical Review

A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 Leading companies in the oral solid dosage market are Catalent, Inc.,

Dosage 98
article thumbnail

France gets new sterile liquid drug manufacturing facility

European Pharmaceutical Review

Positively, it comes at a time when securing fill finish capacity can be a challenge for many pharmaceutical companies. The HPAPI market A 2022 market report showed that due to the small volumes required for dosage, small-scale providers are also gaining importance. HPAPI contract manufacturing to value $14.6

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Advanced Solutions for Sustained Delivery of Ocular Therapies

PharmTech

Pharmaceutical companies have responded with growing investment in the research and development of novel eye treatments and drug delivery systems designed to address key challenges in ocular therapy. Challener News Article Hydrogels, drug-eluting contact lenses, and other implant technologies show real promise.

Dosage 64
article thumbnail

ten23 health Joins Gerresheimer, SCHOTT, Stevanato Group in ‘Alliance for RTU’

PharmTech

The platform provides a means of technical exchange on high-quality, ready-to-fill primary packaging between pharmaceutical companies, contract manufacturers, and contract development and manufacturing organizations.

Dosage 45